Abstract 191P
Background
Several studies have shown improvement in pCR rate with the addition of carboplatinum to the neo-adjuvant chemotherapy (NACT) treatment of stage I-III triple-negative breast cancer (TNBC). However, data on its effects on long-term outcomes such as relapse-free survival and overall survival is not well known. Furthermore, data from ongoing studies addressing these outcomes are currently awaited. We intended to assess pCR, RFS, and OS in this population using our real-world data.
Methods
A retrospective analysis was conducted on patients with Stage I-III TNBC who received standard NACT with or without the addition of carboplatinum at Shaukat Khanum Memorial Cancer Hospital. A comparative analysis was performed between the platinum and non-platinum cohorts, evaluating the patient characteristics, clinical outcomes, and toxicity profiles using statistical methods.
Results
Out of a total of 140 patients, 58 (41%) received carboplatinum AUC 5 (Cb) in addition to the standard NACT backbone of adriamycin, cyclophosphamide, and paclitaxel. The median age for both groups was 38 years. Median follow-up was 17.8 months (7.6 - 59.4) for the overall population. Pathological complete response (pCR) was achieved in 62% of patients in the Cb arm compared to 46% in the non-Cb arm (p=0.057). Relapse-free survival (RFS) at 3 years was 87% in Cb containing arm vs. 79% in the non-Cb arm (p=0.37). Overall survival at 3 years was 100% in the Cb arm compared to the 91.6% in the non-Cb arm (p=0.04). Ki67 and ECOG performance status were independently associated with the probability of achieving pCR, (p=0.004 and 0.03), respectively. Statistically significant higher rates of mucositis (59% vs. 40%), cytopenias (17% vs. 1%), gastrointestinal toxicity (69% vs. 43%) were noted in the Cb containing arm compared to the non-Cb arm.
Conclusions
Our real-world data shows that the addition of carboplatinum to standard NACT in the treatment of stage I-III TNBC resulted in a statistically significant improvement in pCR rate and 3-year OS. The use of Cb was associated with a higher but manageable toxicities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.